Thomas Nguyen, MD
Pain Medicine · Reston, VANPI 1437265667
Payments from drug & device makers
What this record shows
This record is dominated by food and beverage: $5,086 of the $5,988 with a category attached, or 84.9%. 28 manufacturers reported payments, led by Abbott at 37.6% of the total. Reporting peaked in 2022 at $1,532 and has fallen 70.0% since, to $460 in 2025.
Across 155 payments — averaging $38.63 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Abbott$2K
- Nevro Corp.$723
- Medtronic$661
- AbbVie$276
- MML US, Inc.$213
- Vertos Medical, Inc.$186
- plus $2K from 22 others
Across 6 payments — averaging $566.67 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Nevro Corp.$3K
What the payments were for
- Travel & lodging$90215%
- Food & beverage$5,08685%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Abbott | 38 | $2,252 |
| Nevro Corp. | 13 | $723 |
| Medtronic(2 entities) | 40 | $661 |
| AbbVie | 10 | $276 |
| MML US, Inc. | 3 | $213 |
| Vertos Medical, Inc. | 2 | $186 |
| Stimwave Technologies Incorporated | 1 | $180 |
| Collegium Pharmaceutical, Inc. | 9 | $163 |
| Averitas Pharma Inc. | 2 | $153 |
| Biodelivery Sciences International, Inc. | 7 | $144 |
| Bioventus LLC | 2 | $122 |
| Boston Scientific | 4 | $111 |
| Aesculap Implant Systems, LLC | 3 | $109 |
| GRT US Holding, Inc. | 3 | $107 |
| Novo Nordisk | 1 | $105 |
| SPR Therapeutics, Inc | 1 | $96 |
| Redhill Biopharma Inc. | 1 | $71 |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 3 | $48 |
| Protega Pharmaceutials Inc | 1 | $47 |
| Pfizer | 2 | $38 |
| Azurity Pharmaceuticals, Inc. | 2 | $37 |
| Pacira Therapeutics, Inc. | 1 | $33 |
| IBSA Pharma Inc. | 1 | $23 |
| Supernus Pharmaceuticals, Inc. | 1 | $22 |
| Vertex | 1 | $19 |
| Sanofi-aventis U.S. LLC | 1 | $19 |
| Curonix LLC | 1 | $18 |
| Hikma Pharmaceuticals USA | 1 | $13 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- Proclaim IPG$597
- PROCLAIM$448
- Senza Spinal Cord Stimulation System$300
- Proclaim Family of SCS IPGs$297
- Axium$273
- ReActiv8$205
- mild Device Kit$160
- Senza$155
- INCEPTIV$134
- Qutenza$128
- Wegovy$105
How this compares
$5,988 in reported general payments places this provider in the 75th percentile of 150 pain medicine providers in Virginia.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| PercocetOxycodone Hcl/Acetaminophen | 16 | $71,975 |
| OxycontinOxycodone Hcl | 63 | $41,570 |
| Xtampza ErOxycodone Myristate | 33 | $15,667 |
| MovantikNaloxegol Oxalate | 23 | $14,167 |
| Oxycodone Hcl | 520 | $12,557 |
| Morphine Sulfate ErMorphine Sulfate | 311 | $9,195 |
| Buprenorphine | 15 | $6,135 |
| Metaxalone | 13 | $5,497 |
| Morphine Sulfate | 112 | $5,036 |
| Fentanyl | 35 | $4,934 |
| Pregabalin | 149 | $4,226 |
| Gabapentin | 255 | $4,187 |
| Oxycodone-AcetaminophenOxycodone Hcl/Acetaminophen | 193 | $4,149 |
| Hydrocodone-AcetaminophenHydrocodone/Acetaminophen | 147 | $3,987 |
| Lidocaine | 20 | $3,269 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Collegium Pharmaceutical, Inc.Xtampza Er | $163 | $15,66733 claims |
| Redhill Biopharma Inc.Movantik | $71 | $14,16723 claims |
| Hikma Pharmaceuticals USABuprenorphine, Morphine Sulfate | $13 | $11,170127 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 75th percentile of 150 pain medicine providers in Virginia.
Other pain medicine in Reston
- Riju DasguptaReston$7K
- Omesh SinghReston$3K
- Haroon HameedReston$3K
- Chheany UngRoanoke$198K
- Daniel KendallMc Lean$100K
- Steven GershonVirginia Beach$78K
- Jared DavisFishersville$45K
- Nameer HaiderWoodbridge$36K
- Lynn KohanCharlottesville$30K
- George BaylorSalem$24K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.